Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Analysts are expecting strong performance driven by the strong demand of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential challenge